CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 113 enrolled
Drug / intervention
Peginterferon alfa-2b (SCH 54031) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00705263
NCT00705263N/ACompleted
CompareCT.gov

Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Slovenia

Schering-Plough·observational·Posted Jun 26, 2008·Updated Aug 25, 2009

In Brief

An observational study evaluating Peginterferon alfa-2b (SCH 54031) and Ribavirin (SCH 18908) for Hepatitis C, Chronic and Hepacivirus. Completed, enrolled 113 participants.

Detailed Summary

The current gold standard for treatment of chronic hepatitis C is pegylated interferon plus ribavirin. Drug administration accuracy and ease of use will definitely determine treatment effectiveness. This is the idea behind the development and usage of the PegIntron pen (PegPen). Therefore, it is worthwhile to evaluate patients' satisfaction with this novel device. The results of the study will be used to improve PegPen training techniques for patients and health care providers.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic, Hepacivirus
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 26, 2008
Enrollment StartOct 1, 2005
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 18.0 years ago

Interventions

Peginterferon alfa-2b (SCH 54031)biological

Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.

Ribavirin (SCH 18908)drug

Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.